Genetic services for hereditary breast/ovarian and colorectal cancers - Physicians' awareness, use and satisfaction

被引:30
|
作者
Carroll, J. C. [1 ,2 ]
Cappelli, M. [8 ]
Miller, F. [3 ,4 ]
Wilson, B. J. [5 ,6 ]
Grunfeld, E. [9 ,10 ]
Peeters, C. [7 ]
Hunter, A. G. W. [8 ]
Gilpin, C. [8 ]
Prakash, P. [1 ]
机构
[1] Univ Toronto, Mt Sinai Hosp, Granovsky Gluskin Family Med Ctr, Toronto, ON M5T 3L9, Canada
[2] Univ Toronto, Dept Family & Community Med, Family Healthcare Res Unit, Toronto, ON M5T 3L9, Canada
[3] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[4] McMaster Univ, Dept Hlth Aging & Soc, Hamilton, ON, Canada
[5] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada
[6] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada
[7] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada
[8] Childrens Hosp Eastern Ontario, Genet Patient Serv Unit, Ottawa, ON K1H 8L1, Canada
[9] Dalhousie Univ, Canc Outcomes Res Program, Halifax, NS, Canada
[10] Dalhousie Univ, Dept Med, Halifax, NS, Canada
关键词
awareness; breast neoplasm; colorectal neoplasm; hereditary cancer; ovarian neoplasm; physicians;
D O I
10.1159/000111639
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objectives: In 2000, the Ministry of Health in Ontario, Canada, introduced a publicly funded program to provide genetic services for hereditary breast/ovarian and colorectal cancers. We surveyed physicians to determine their awareness, use and satisfaction with this program. Methods: A self-administered questionnaire was mailed to a random sample of 25% of Ontario family physicians and all gynecologists, oncologists (radiation, surgical and medical), gastroenterologists and general surgeons. Results: Response rate was 49% (n = 1,427). Awareness of genetic testing for breast/ovarian cancer was high (91%) but less for colorectal cancer (60%). Use of services was associated with physician age of 40 or greater, urban location, confidence in knowledge of referral criteria and core competencies in genetics, and awareness of the program and where to refer. Almost half were dissatisfied with notification about the program. Conclusions: Ontario physicians are aware of cancer genetics services, and use is associated with increased knowledge of services, and confidence in skills. They would like more timely services and education about hereditary cancers and susceptibility testing. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 50 条
  • [31] The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer
    Ortmann, O.
    Schueler-Toprak, S.
    Kast, K.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (09)
  • [32] Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers
    Michels, Kara A.
    Pfeiffer, Ruth M.
    Brinton, Louise A.
    Trabert, Britton
    JAMA ONCOLOGY, 2018, 4 (04) : 516 - 521
  • [33] An overview of genetic services delivery for hereditary breast cancer
    Reid, Sonya
    Spalluto, Lucy B.
    Lang, Katie
    Weidner, Anne
    Pal, Tuya
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (03) : 491 - 500
  • [34] An overview of genetic services delivery for hereditary breast cancer
    Sonya Reid
    Lucy B. Spalluto
    Katie Lang
    Anne Weidner
    Tuya Pal
    Breast Cancer Research and Treatment, 2022, 191 : 491 - 500
  • [35] PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
    Mehta, Prashant
    Bothra, Sneha J.
    ADVANCES IN GENETICS, VOL 108, 2021, 108 : 35 - 80
  • [36] Identification and management of hereditary breast-ovarian cancers (2004 update)
    Eisinger, F.
    Bressac, B.
    Castaigne, D.
    Cottu, P. -H.
    Lansac, J.
    Lefranc, J. -P.
    Lesur, A.
    Nogues, C.
    Pierret, J.
    Puy-Pernias, S.
    Sobol, H.
    Tardivon, A.
    Tristant, H.
    Villet, R.
    PATHOLOGIE BIOLOGIE, 2006, 54 (04): : 230 - 250
  • [37] The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
    Drew, Yvette
    Calvert, Hilary
    RECENT ADVANCES IN CLINICAL ONCOLOGY, 2008, 1138 : 136 - 145
  • [38] Noninherited genetic alteration discovered for breast and ovarian cancers
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (03): : 255 - +
  • [39] Novel cancer-associated germline variants in patients with breast, ovarian or colorectal cancers and suspected hereditary cancer syndromes
    Makarova, Maria
    Danishevich, Anastasiia
    Bodunova, Natalia
    Nemtsova, Marina
    Chernevskiy, Denis
    Krinitsina, Anastasia
    Belenikin, Maxim
    Baranova, Elena
    Sagaidak, Olesya
    Antonenko, Aleksey
    Ulanova, Polina
    Byakhova, Maria
    Semenova, Anna
    Galkin, Vsevolod
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 266 - 266
  • [40] Previously unrecognized genetic mutations in colorectal and breast cancers
    Nature Clinical Practice Oncology, 2007, 4 (1): : 9 - 9